High serum osteoprotegerin levels in patients with hyperthyroidism: Effect of medical treatment

Bone

Volumn 35, Issue 3, 2004, Pages 785-791

  Amato, G ^a   Mazziotti, G ^a   Sorvillo, F ^a   Piscopo, M ^a   Lalli, E ^a   Biondi, B ^b   Iorio, S ^a   Molinari, A ^a   Giustina, A ^c   Carella, C ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Autoimmune disease; Bone metabolism; Hyperthyroidism; Osteoprotegerin; Thyroid hormones

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; LIOTHYRONINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE;

ADULT; AGE DISTRIBUTION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE RADIOGRAPHY; BONE STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; EUTHYROIDISM; EVALUATION; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SAMPLE SIZE; SEX RATIO; THYROTROPIN BLOOD LEVEL; TOXIC GOITER;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; HYPERTHYROIDISM; MALE; METHIMAZOLE; MIDDLE AGED; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC; THYROID HORMONES;

EID: 4344560813     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.04.021     Document Type: Article

References (30)

1. Olkawa M., Kushida K., Takahashi M., et al. Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin. Endocrinol. 50:1999;171-176
2. Isaia G.C, Roggia C., Gola D., Stefano M.D, Gallone G., Aimo G., et al. Bone turnover in hyperthyroidism before and after thyrostatic management. J. Endocrinol. Invest. 23:2000;727-731
3. Pantazi H., Papapetrou P.D. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J. Clin. Endocrinol. Metab. 85:2000;1099-1106
4. Akalin A., Colak O., Alatas O., Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin. Endocrinol. 57:2002;125-129
5. Siddiqi A., Monson J.P., Wood D.F., Besser G.M., Burrin J.M. Serum cytokines in thyrotoxicosis. J. Clin. Endocrinol. Metab. 84:1999;435-439
6. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319
7. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176
8. Burgess T.L., Qian Y., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145:1999;527-538
9. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:1999;345-357
10. Hofbauer L.C., Heufelder A.E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79:2001;243-253
11. Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247:1998;610-615
12. Yano K., Tsuda E., Washida N., Kobayashi F., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14:1999;518-527
13. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16:2001;348-360
14. Ueland T., Bollerslev J., Godang K., Muller F., Froland S.S., Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - Possible role in bone homeostasis. Eur. J. Endocrinol. 145:2001;685-690
15. Misra M., Soyka L.A., Miller K.K., Herzog D.B., Grinspoon S., De Chen D., et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 88:2003;3816-3822
16. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr. Opin. Rheumatol. 15:2003;454-457
17. Hofbauer L.C., Schoppet M. Serum measurement of osteoprotegerin - Clinical relevance and potential applications. Eur. J. Endocrinol. 145:2001;681-683
18. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol. 22:2002;549-553
19. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 106:2002;1192-1194
20. Ziolkowska M., Kurowska M., Radzikowska A., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum. 46:2002;1744-1753
21. Cooper D.S. Hyperthyroidism. Lancet. 362:2003;459-468
22. Reginster J.Y., Dethor M., Pirenne H., Dewe W., Albert A. Reproducibility and diagnostic sensitivity of ultrasonometry of the phalanges to assess osteoporosis. Int. J. Gynaecol. Obstet. 63:1998;21-28
23. Wuster C., Albanese C., De Aloysio D., et al. Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity, and discrimination power. The Phalangeal Osteosonogrammetry Study Group. J. Bone Miner. Res. 15:2000;1603-1614
24. Costagliola S., Morgenthaler N.G., Hoermann R., et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J. Clin. Endocrinol. Metab. 84:1999;90-97
25. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., Willvonseder R Austrian Study Group Normative values of bone metabolism serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 32:2003;681-686
26. Varga F., Spitzer S., Klaushofer K. Triiodothyronine (T3) and 1, 25-dihydroxyvitamin D3 (1, 25D(3)) inversely regulate OPG gene expression in dependence of osteoblastic phenotype. Calcif. Tissue Int. 74:2004;382-387
27. Fahrleitner-Pammer A., Dobnig H., Piswanger-Soelkner C., Bonelli C., Dimai H.P., Leb G., et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien. Klin. Wochenschr. 115:2003;291-297
28. Hofbauer L.C., Kluger S., Kuhne C.A., Dunstan C.R., Burchert A., Schoppet M., et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J. Cell. Biochem. 86:2002;642-650
29. Paschke R., Ludgate M. The thyrotropin receptor in thyroid diseases. N. Engl. J. Med. 337:1997;1675-1681
30. Abe E., Marians R.C., Yu W., et al. TSH is a negative regulator of skeletal remodelling. Cell. 115:2003;129-130